-$0.13 Earnings Per Share Expected for Anixa Biosciences, Inc. (NASDAQ:ANIX) This Quarter

Equities research analysts forecast that Anixa Biosciences, Inc. (NASDAQ:ANIXGet Rating) will report earnings of ($0.13) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anixa Biosciences’ earnings. Anixa Biosciences posted earnings of ($0.08) per share during the same quarter last year, which would suggest a negative year over year growth rate of 62.5%. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Anixa Biosciences will report full-year earnings of ($0.52) per share for the current year. For the next financial year, analysts anticipate that the company will post earnings of ($0.61) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Anixa Biosciences.

Separately, Zacks Investment Research raised shares of Anixa Biosciences from a “sell” rating to a “buy” rating and set a $3.00 target price for the company in a report on Tuesday, March 29th.

Hedge funds have recently added to or reduced their stakes in the company. Adirondack Trust Co. acquired a new stake in shares of Anixa Biosciences in the third quarter valued at approximately $33,000. Cedar Brook Financial Partners LLC acquired a new stake in Anixa Biosciences during the third quarter worth approximately $48,000. Millennium Management LLC acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $47,000. Goldman Sachs Group Inc. acquired a new stake in Anixa Biosciences during the fourth quarter worth approximately $49,000. Finally, B. Riley Wealth Management Inc. boosted its position in Anixa Biosciences by 41.7% during the fourth quarter. B. Riley Wealth Management Inc. now owns 17,000 shares of the company’s stock worth $50,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 10.51% of the company’s stock.

Shares of ANIX opened at $2.55 on Friday. Anixa Biosciences has a fifty-two week low of $2.30 and a fifty-two week high of $5.87. The firm has a 50-day simple moving average of $2.74 and a 200-day simple moving average of $3.39.

About Anixa Biosciences (Get Rating)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

Further Reading

Get a free copy of the Zacks research report on Anixa Biosciences (ANIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.